Empirical Studies of Effects of High Blood Pressure on Medical Costs and Heart Disease: Is the 2017 ACC/AHA Guideline Supported by Enough Evidence? — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Empirical Studies of Effects of High Blood Pressure on Medical Costs and Heart Disease: Is the 2017 ACC/AHA Guideline Supported by Enough Evidence?
Graduate School of Engineering, University of Tokyo and Research Institute of Economy, Trade and Industry (RIETI), Tokyo, Japan
,
The Public Health Institute, Tokyo, Japan
1 Graduate School of Engineering, University of Tokyo and Research Institute of Economy, Trade and Industry (RIETI), Tokyo, Japan
Background: The American College of Cardiology (ACC), American Heart Association (AHA) and other organizations announced a new hypertension guideline in November 2017. However, previous studies have pointed out that this new guideline might lack sufficient evidence to justify its use. Data and Methods: The effects of blood pressure (BP) on medical costs and on the probability of having heart disease as anamnesis are analyzed. We used a dataset containing 175,123 medical checkups and 6,312,125 receipts from 88,211 individuals obtained from three health insurance societies from April 2013 to March 2016. The dataset was divided into subgroups based on whether the patients had diabetes and took hypertension medications. The power transformation and probit models were used in the study. Results: We observed negative effects of systolic BP (SBP) on medical costs in most subgroups. We could not find evidence that higher SBP made the medical costs and probability of having heart diseases higher. The results raise uncertainty about the reliability of the new guideline, at least for SBP. Conclusion: The results of this study did not support the new 2017 ACC/AHA guideline, at least for SBP. The new guideline must be more carefully reevaluated by additional studies. Limitations: The dataset was observatory, the sample period was only 3 years, and we could not complete a time-series analysis of individuals.
Keywords2017 ACC/AHA Hypertension GuidelineHypertensionBlood PressureMedical CostsCardiovascular and Heart Disease
Whelton, P.K., Carey, R.M., Arrow, W.S. et al. (Writing Committee Members) (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71, e13-e115. (Correction: Hypertension, e140-e144.)
Whelton, P.K., Carey, R.M., Arrow, W.S., et al. (2018) 2017 Guideline for Blood Pressure in Adults. American College of Cardiology. http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults
Carey, R.M. and Whelton P.K. for the 2017 ACC/AHA Hypertension Guideline Writing Committee (2018) Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Annals of Internal Medicine, 168, 351-335. https://doi.org/10.7326/M17-3203
Chobanian, A.V., Bakris, G.L., Black, H.B., et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252. https://doi.org/10.1161/01.HYP.0000107251.49515.c2
National Heart, Lung, and Blood Institute, U.S. Department of Health and Human Services (2004) National High Blood Pressure Education Program: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (Complete Report). https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf
American Academy of Family Physicians (AAFP) (2017) AAFP Decides to Not Endorse AHA/ACC Hypertension Guideline, Academy Continues to Endorse JNC8 Guideline. AAFP News. https://www.aafp.org/news/health-of-the-public/20171212notendorseaha-accgdlne.html
Wright, J.T., Williamson, J.D., Whelton, P.K., et al. (SPRINT Research Group) (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 373, 2103-2116. https://doi.org/10.1056/NEJMoa1511939
Pak, T.R., Rodriguez, M.D. and Roth, F.P. (2015) Why Clinical Trials Are Terminated. bio-Rxiv. https://www.biorxiv.org/content/biorxiv/early/2015/07/02/021543.full.pdf
Harvard Health Publishing (2017) The Power of the Placebo Effect. Harvard Medical School. https://www.health.harvard.edu/mental-health/the-power-of-the-placebo-effect
Hoenemeyer, T.W., Kaptchuk, T.J., Mehta, T.S., et al. (2018) Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. Scientific Reports, 8, 2784. https://doi.org/10.1038/s41598-018-20993-y
The ACCORD Study Group (2010) Effect of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 362, 1575-1585. https://doi.org/10.1056/NEJMoa1001286
Lewington, S., Clarke, R., Qizilbash, N., et al. (2002) Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies. Lancet, 360, 1903-1913. https://doi.org/10.1016/S0140-6736(02)11911-8
Nawata, K., Sekizawa, Y. and Kimura, M. (2018) Evaluation of Blood Pressure Control Medicines Using Health and Medical Checkup Data in Japan: Alternative Methods for Randomized Controlled Trials. Health, 10, 587-603. https://doi.org/10.4236/health.2018.105047
Dickersin, K., Chan, S., Chalmersx, T.C., et al. (1987) Publication Bias and Clinical Trials. Controlled Clinical Trials, 8, 343-353. https://doi.org/10.1016/0197-2456(87)90155-3
Hopewell, S., Loudon, K., Clarke, M.J., et al. (2009) Publication Bias in Clinical Trials Due to Statistical Significance or Direction of Trial Results, (Review). Cochrane Database of Systematic Reviews, No. 1, MR000006. http://sverigesradio.se/diverse/appdata/isidor/files/83/5775.pdf
Lexchin, J., Bero, L.A., Djulbegovic, B.B., et al. (2003) Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review. BMJ, 326. https://doi.org/10.1136/bmj.326.7400.1167
Gorman, B.K. and Porter, J.R. (2011) Social Networks and Support, Gender, and Radical/Ethic Disparities in Hypertension among Older Adults. Population Research & Policy Review, 20, 885-911. https://doi.org/10.1007/s11113-011-9215-4
Ibrahim, M.M. and Damasceno, A. (2012) Hypertension in Developing Countries. The Lancet, 380, 611-619. https://doi.org/10.1016/S0140-6736(12)60861-7
Omiboni, S., Aristizabal, D., De la Sierra, A., et al. (2016) Hypertension Types Defined by Clinic and Ambulatory Blood Pressure in 14142 Patients Referred to Hypertension Clinics Worldwide. Data from ARTEMIS Study. Journal of Hypertension, 34, 2187-2198. https://doi.org/10.1097/HJH.0000000000001074
Nawata, K., Matsumoto, A., Kajihara, K., et al. (2017) Evaluation of the Distribution of and Factors Affecting Blood Pressure Using Medical Checkup Data in Japan. Health, 9, 124-137. https://doi.org/10.4236/health.2017.91009
Rapsomaniki, E., Timmis, A., George, J., et al. (2014) Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1.25 Million People. The Lancet, 383, 1899-1911. https://doi.org/10.1016/S0140-6736(14)60685-1
Heckman, J. (1979) Sample Selection Bias as a Specification Error. Econometrica, 47, 153-161. https://doi.org/10.2307/1912352
Muntner, P., Carey, R.M., Gidding, S., et al. (2018) Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Journal of the American College of Cardiology, 71, 109-118. https://doi.org/10.1016/j.jacc.2017.10.073
Nawata, K. and Kimura, M. (2018) Does High Systolic Blood Pressure Truly Increase Medical Expenditure? An Empirical Analysis of the New 2017 ACC/AHA Hypertension Guideline. Health, 10, 1044-1065. https://doi.org/10.4236/health.2018.108079
American Diabetes Association (ADA) (2014) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 37, S81-S90. https://doi.org/10.2337/dc14-S081
ADA (2015) Diabetes Basic. http://www.diabetes.org/
International Diabetes Federation (2018) What Is Diabetes. https://www.idf.org/aboutdiabetes/what-is-diabetes.html
NCD Risk Factor Collaboration (2016) Worldwide Trends in Diabetes since 1980: A Pooled Analysis of 751 Population-Based Studies with 4•4 Million Participants. The Lancet, 387, 1513-1530. https://doi.org/10.1016/S0140-6736(16)00618-8
Diaz-Valencia, P.A., Bougneres, P. and Valleron, A.J. (2015) Global Epidemiology of Type 1 Diabetes in Young Adults and Adults: A Systematic Review. BMC Public Health, 15, 255. https://doi.org/10.1186/s12889-015-1591-y
National Health Service (NHS) (2016) Treatment—High Blood Pressure (Hypertension). https://www.nhs.uk/conditions/high-blood-pressure-hypertension/treatment/
American Heart Association (AHA) (2017) Types of Blood Pressure Medications. http://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
Healthdirect (2017) Blood Pressure Medication. Department of Health. https://www.healthdirect.gov.au/blood-pressure-medication
Healthline Editorial Team (2018) A List of Blood Pressure Medications. https://www.healthline.com/health/high-blood-pressure-hypertension-medication
Nawata, K. and Kimura, M. (2017) Evaluation of Medical Costs of Kidney Diseases and Risk Factors in Japan. Health, 9, 1734-1749. https://doi.org/10.4236/health.2017.913127
Japanese Law Translation (2009) Industrial Safety and Health Act. http://www.japaneselawtranslation.go.jp/law/detail/?id=1926&vm=&re
Nawata, K., Niita, A., Watanabe, S., et al. (2006) An Analysis of the Length of Stay and the Effectiveness of Treatment for Hip Fractured Patients in Japan: Evaluation of the Revision of the 2002 Medical Service Fee Schedule. Journal of Health Economics, 25, 722-739. https://doi.org/10.1016/j.jhealeco.2005.11.002
Centers Disease Control and Prevention (2017) LDL and HDL Cholesterol: “Bad” and “Good” Cholesterol. https://www.cdc.gov/cholesterol/ldl_hdl.htm
AHA (2017) HDL (Good), LDL (Bad) Cholesterol and Triglycerides. http://www.heart.org/HEARTORG/Conditions/Cholesterol/HDLLDLTriglycerides/HDL-Good-LDL-Bad-Cholesterol-and-Triglycerides_UCM_305561_Article.jsp#.WxUKUkjRCUk
Kennel, W.B., Brand, N., Skinner, J.J., et al. (1967) The Relation of Adiposity to Blood Pressure and Development of Hypertension: The Framingham Study. Annals of Internal Medicine, 67, 48-59. https://doi.org/10.7326/0003-4819-67-1-48
Kotchen, T.A. (2010) Obesity-Related Hypertension: Epidemiology, Pathophysiology, and Clinical Management. American Journal of Hypertension, 23, 1170-1178. https://doi.org/10.1038/ajh.2010.172
Jiang, S.-Z., Lu, W., Zong, X.-F., et al. (2016) Obesity and Hypertension. Experimental and Therapeutic Medicine, 12, 2395-2399. https://doi.org/10.3892/etm.2016.3667
Loggi, M., Lombardi, M. and Caldarone, E. (2017) The Relationship between Obesity and Hypertension: A Comprehensive Overview on Twins. Hypertension Research, 40, 947-963. https://doi.org/10.1038/hr.2017.75
MedlinePlus (2018) High Blood Pressure Medicines. U.S. National Library of Medicine. https://medlineplus.gov/ency/article/007484.htm
WebMed (2018) Side Effects of High Blood Pressure Medications. https://www.webmd.com/hypertension-high-blood-pressure/guide/side-effects-high-blood-pressure-medications#1
Harvard Heath Publishing (2017) Controlling Blood Pressure with Fewer Side Effects. Harvard Medical Sc[1]hool. https://www.health.harvard.edu/heart-health/controlling-blood-pressure-with-fewer-side-effects